Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Cepheid, Cancer Genetics Appoint New Execs


Cepheid said this week that it has appointed James Post to the position of executive vice president of North American commercial operations.

Post joins Cepheid from Alere, where he most recently served as global president of acute care. Post spent ten years at Alere and its predecessor companies Inverness Medical and Biosite. Prior to Alere, he spent approximately ten years at the United States Surgical Corporation in a variety of sales and marketing positions, including vice president of sales.

Cancer Genetics said this week that Christopher Mitton has joined the company as director of national account development and sales operations.

Mitton will lead the national expansion of CGI's Expand Dx program, designed to increase outreach and patient value for community hospitals and labs by expanding their cancer diagnostic capabilities through new testing methodologies and collaborative services. He most recently led North American sales of leukemia and solid tumor molecular diagnostic tests for Qiagen, and prior to that held diagnostic sales roles with Ipsogen, Bayer Healthcare, Abbott Diagnostics, and BioChem Immunosystems.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.